Nanobody Affinity Maturation using Phage Display Selection
Awarded Limited / Sole Source Justification Posted
- Solicitation number
- 75N91025Q00049
- Agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N91025P00452 Federal contract award
- Awardee
- Creative Biolabs Inc.
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- Q301 Reference Laboratory Testing
- Place of performance
- Rockville, Maryland, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The National Cancer Institute (NCI), part of the National Institutes of Health, issued a sole source justification to acquire specialized nanobody affinity maturation services for cancer research applications. The contract, awarded to Creative Biolabs Inc. on September 11, 2025, requires the contractor to perform targeted affinity maturation of an anti-human BCMA nanobody through phage display library construction and selection over a six-month base period. The project aims to deliver five affinity-optimized nanobody sequences along with sufficient purified protein for in vitro and in vivo testing, specifically targeting B-cell maturation antigen (BCMA) for imaging and therapeutic applications in multiple myeloma treatment. The sole source justification was based on Creative Biolabs' proprietary expertise in nanobody engineering, their possession of the original nanobody sequence, and specialized mutagenesis platforms that other vendors could not replicate. The NCI conducted extensive market research, including engagement with three NCI laboratories and Genscript, but no alternative sources could meet the technical specifications, and no capability statements were received following a July 18, 2025 solicitation notice posted on SAM.gov. While the contract award amount was not disclosed in the available documentation, the firm-fixed-price research and development contract represents a critical component of the agency's cancer research initiatives.
Notice text
The purpose of this purchase order is to acquire services to perform targeted affinity maturation of an anti-human BCMA nanobody via
phage display library construction and selection. The objective is to deliver five affinity-optimized nanobody sequences along with sufficient purified protein for in vitro and in vivo testing.
Awarded contract 75N91025P00452 to unknown vendor for unknown amount on 2025-09-11.
Files
| File | Type | Posted |
|---|---|---|
| SSJ Nanobody_Redacted.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Limited / Sole Source Justification | |
| Nanobody Affinity Maturation using Phage Display Selection | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| NCI OA Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research” | National Cancer Institute | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity